EXEL vs. EDIT

Last updated Jun 9, 2026

EXEL (Exelixis, Inc.) and EDIT (Editas Medicine, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, EXEL returned 21.50%/yr vs -21.70%/yr for EDIT. At a 0.38 correlation, their price movements are largely independent.

Performance

EXEL vs. EDIT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exelixis, Inc. (EXEL) and Editas Medicine, Inc. (EDIT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, EXEL achieves a 18.05% return, which is significantly lower than EDIT's 29.02% return. Over the past 10 years, EXEL has outperformed EDIT with an annualized return of 21.50%, while EDIT has yielded a comparatively lower -21.70% annualized return.

EXEL

• 1D: -1.82%
• 1M: 7.43%
• YTD: 18.05%
• 6M: 22.69%
• 1Y: 20.24%
• 3Y*: 39.16%
• 5Y*: 17.83%
• 10Y*: 21.50%

EDIT

• 1D: -2.40%
• 1M: -14.95%
• YTD: 29.02%
• 6M: 9.30%
• 1Y: 38.48%
• 3Y*: -35.09%
• 5Y*: -40.81%
• 10Y*: -21.70%

*Multi-year figures are annualized to reflect compound growth (CAGR)

EXEL vs. EDIT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EXEL Exelixis, Inc.	18.05%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-10.42%	-35.30%	103.89%
EDIT Editas Medicine, Inc.	29.02%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%

Correlation

The correlation between EXEL and EDIT is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.29
Correlation (3Y) Calculated over the trailing 3-year period	0.27
Correlation (5Y) Calculated over the trailing 5-year period	0.36
Correlation (10Y) Calculated over the trailing 10-year period	0.39
Correlation (All Time) Calculated using the full available price history since Feb 4, 2016	0.38

The correlation between EXEL and EDIT shifts across timeframes, from 0.27 (3 years) to 0.39 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap EXEL : $13.83B EDIT : $258.89M
EPS EXEL : $3.00 EDIT : -$1.21
PS Ratio EXEL : 6.06 EDIT : 6.66
PB Ratio EXEL : 7.15 EDIT : 58.73
Total Revenue (TTM) EXEL : $2.38B EDIT : $35.86M
Gross Profit (TTM) EXEL : $1.70B EDIT : $35.86M
EBITDA (TTM) EXEL : $991.79M EDIT : -$76.66M

Return for Risk

EXEL vs. EDIT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EXEL

EXEL Risk / Return Rank: 58
EXEL Sharpe Ratio Rank: 60
EXEL Sortino Ratio Rank: 53
EXEL Omega Ratio Rank: 56
EXEL Calmar Ratio Rank: 60
EXEL Martin Ratio Rank: 61

EDIT

EDIT Risk / Return Rank: 58
EDIT Sharpe Ratio Rank: 56
EDIT Sortino Ratio Rank: 63
EDIT Omega Ratio Rank: 59
EDIT Calmar Ratio Rank: 57
EDIT Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EXEL vs. EDIT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EXEL	EDIT	Difference
Sharpe ratio: Return per unit of total volatility	0.50	0.41	+0.10
Sortino ratio: Return per unit of downside risk	0.92	1.32	-0.40
Omega ratio: Gain probability vs. loss probability	1.13	1.15	-0.02
Calmar ratio: Return relative to maximum drawdown	0.81	0.65	+0.16
Martin ratio: Return relative to average drawdown	1.94	1.15	+0.80
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EXEL vs. EDIT - Sharpe Ratio Comparison

The current EXEL Sharpe Ratio is 0.50, which is comparable to the EDIT Sharpe Ratio of 0.41. The chart below compares the historical Sharpe Ratios of EXEL and EDIT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	EXEL	EDIT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.50	0.41	+0.10
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.48	-0.44	+0.92
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.49	-0.26	+0.75
Sharpe Ratio (All Time) Calculated using the full available price history	0.08	-0.20	+0.28

Drawdowns

EXEL vs. EDIT - Drawdown Comparison

The maximum EXEL drawdown since its inception was -97.38%, roughly equal to the maximum EDIT drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for EXEL and EDIT.

Drawdown Indicators

	EXEL	EDIT	Difference
Max Drawdown Largest peak-to-trough decline	-97.38%	-98.92%	+1.54%
Max Drawdown (1Y) Largest decline over 1 year	-25.16%	-59.88%	+34.72%
Max Drawdown (3Y) Largest decline over 3 years	-25.34%	-91.46%	+66.12%
Max Drawdown (5Y) Largest decline over 5 years	-36.12%	-98.66%	+62.54%
Max Drawdown (10Y) Largest decline over 10 years	-57.20%	-98.92%	+41.72%
Current Drawdown Current decline from peak	-1.82%	-97.08%	+95.26%
Average Drawdown Average peak-to-trough decline	-71.08%	-62.60%	-8.48%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.44%	33.66%	-23.22%

Volatility

EXEL vs. EDIT - Volatility Comparison

The current volatility for Exelixis, Inc. (EXEL) is 11.21%, while Editas Medicine, Inc. (EDIT) has a volatility of 31.99%. This indicates that EXEL experiences smaller price fluctuations and is considered to be less risky than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EXEL	EDIT	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.21%	31.99%	-20.78%
Volatility (6M) Calculated over the trailing 6-month period	25.96%	61.53%	-35.57%
Volatility (1Y) Calculated over the trailing 1-year period	40.34%	95.12%	-54.78%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	37.17%	94.12%	-56.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	44.47%	83.83%	-39.36%

Dividends

EXEL vs. EDIT - Dividend Comparison

Neither EXEL nor EDIT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both EXEL and EDIT in my portfolio?

EXEL and EDIT have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, EXEL or EDIT?

EDIT has higher volatility (31.99%) compared to EXEL (11.21%). In terms of maximum drawdown, EXEL dropped -97.38% vs EDIT's -98.92%.

Which has better risk-adjusted returns?

EXEL currently has the higher Sharpe Ratio (0.50 vs 0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.